Tyneside pharma firm Shield Therapeutics seeks to raise $10m through subscription by largest investor
2025-09-16 03:37:57 By
Pharma company Shield Therapeutics has announced a subscription by its largest investor to raise $10m.
The company’s main product, which treats iron deficiency anaemia, was first launched in Europe under the Ferracru brand in 2019 but is now available in the US and other countries as Accrufer. The Newcastle company has signed an agreement with AOP Health International Management AG, in which the major shareholder has conditionally agreed to subscribe for 256,410,256 new ordinary shares.
The agreement is part of a broader funding move, which sees the firm launch a conditional offer for its existing retail shareholders to purchase new ordinary shares, aiming to raise up to £1m. AOP’s subscription is subject to shareholder approval at a general meeting scheduled for December 24, where a waiver of obligations under the Takeover Code will be considered, because its large increase in shares would take it past the threshold to trigger a formal company takeover. The Austrian company, however, has said that is not part of its plans.
The announcement says: “AOP has stated to the company that it is not prepared to proceed with an equity investment in the company unless it obtains a controlling interest (i.e. greater than 50% of the Enlarged Share Capital) as a result. Such a subscription is conditional upon the approval of the resolutions by the shareholders at the General Meeting (including the Waiver Resolution) and the Subscription Admission.
“If such approvals are not provided, AOP will not be required to proceed with an equity investment in the company, resulting in the company not receiving the aggregate gross proceeds of at least $10m, which would otherwise have helped the company achieve its aim of becoming cash flow positive by the end of the calendar year of 2025.
“In the event that the maximum number of Retail Book Offer Shares are issued, following the completion of the Subscription, AOP will hold 568,007,521 Ordinary Shares, representing 53%. The proposed Subscription gives rise to certain considerations under the Takeover Code. AOP has confirmed that it is not prepared to make a mandatory offer for the company.”